- Home
- GOSS vs PHLT Comparison
GOSS vs PHLT Comparison
Compare GOSS & PHLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- PHLT
- Stock Information
- Founded
- GOSS 2015
- PHLT 1976
- Country
- GOSS United States
- PHLT United States
- Employees
- GOSS N/A
- PHLT N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- PHLT Other Consumer Services
- Sector
- GOSS Health Care
- PHLT Consumer Discretionary
- Exchange
- GOSS Nasdaq
- PHLT Nasdaq
- Market Cap
- GOSS 203.3M
- PHLT N/A
- IPO Year
- GOSS 2019
- PHLT N/A
- Fundamental
- Price
- GOSS $1.12
- PHLT $2.25
- Analyst Decision
- GOSS Strong Buy
- PHLT
- Analyst Count
- GOSS 4
- PHLT 0
- Target Price
- GOSS $7.50
- PHLT N/A
- AVG Volume (30 Days)
- GOSS 1.6M
- PHLT 124.3K
- Earning Date
- GOSS 05-13-2025
- PHLT 05-08-2025
- Dividend Yield
- GOSS N/A
- PHLT N/A
- EPS Growth
- GOSS N/A
- PHLT N/A
- EPS
- GOSS N/A
- PHLT N/A
- Revenue
- GOSS $114,701,000.00
- PHLT $122,981,000.00
- Revenue This Year
- GOSS N/A
- PHLT $10.03
- Revenue Next Year
- GOSS $172.31
- PHLT $11.87
- P/E Ratio
- GOSS N/A
- PHLT N/A
- Revenue Growth
- GOSS N/A
- PHLT 8.12
- 52 Week Low
- GOSS $0.50
- PHLT $2.23
- 52 Week High
- GOSS $1.55
- PHLT $4.35
- Technical
- Relative Strength Index (RSI)
- GOSS 56.55
- PHLT N/A
- Support Level
- GOSS $1.06
- PHLT N/A
- Resistance Level
- GOSS $1.26
- PHLT N/A
- Average True Range (ATR)
- GOSS 0.11
- PHLT 0.00
- MACD
- GOSS 0.04
- PHLT 0.00
- Stochastic Oscillator
- GOSS 70.09
- PHLT 0.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.